AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23604335 — intervention group
Group type: COMPARATOR
Intervention: Ex-smokers
Number of subjects: 64
Study 23604335 — intervention group
Group type: COMPARATOR
Intervention: Never-smokers
Number of subjects: 64
Study 21572163 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine
Number of subjects: 421
Study 21572163 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine
Number of subjects: 421
Study 21572163 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 421
Study 21572163 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 421
Study 17629752 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and cyclophosphamide (AC) followed by cyclophosphamide, methotrexate, fluorouracil (CMF)
Number of subjects: 2215
Study 17629752 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hemoglobin and white blood cells (WBC)
Number of subjects: 2215
Study 17629752 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, surgery type, platelets, body mass index, and length of time from surgery to chemotherapy
Number of subjects: 2215
Study 17629752 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression analysis
Number of subjects: 2215
Study 17371885 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy with tapered high-dose prednisone (group 3)
Number of subjects: 508
Study 17371885 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy with infliximab (group 4)
Number of subjects: 508
Study 17371885 — intervention group
Group type: COMPARATOR
Intervention: Sequential monotherapy (group 1)
Number of subjects: 508
Study 17371885 — intervention group
Group type: COMPARATOR
Intervention: Step-up combination therapy (group 2)
Number of subjects: 508
Study 15125017 — intervention group
Group type: EXPERIMENTAL
Intervention: Manuka honey (UMF 15)
Number of subjects: 30
Study 15125017 — intervention group
Group type: COMPARATOR
Intervention: Sugarless chewing gum (control)
Number of subjects: 30
Study 11351935 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 hours of smoking deprivation (tobacco-deprived smokers)
Number of subjects: 55
Study 11351935 — intervention group
Group type: COMPARATOR
Intervention: Nondeprived smokers
Number of subjects: 55
Study 11351935 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 55
Study 11351935 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers (both deprived and nondeprived)
Number of subjects: 55
Study 11351935 — intervention group
Group type: COMPARATOR
Intervention: Smoking deprivation
Number of subjects: 55
Study 9141930 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 41
Study 9141930 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 41
Study 9141930 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 41
Study 9141930 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 41
Study 8201375 — intervention group
Group type: EXPERIMENTAL
Intervention: CYVADIC chemotherapy (cyclophosphamide 500 mg/m2 IV bolus on day 1, vincristine 1.4 mg/m2 IV bolus on day 1, doxorubicin 50 mg/m2 IV bolus on day 1, dacarbazine 400 mg/m2 by 1-hour infusion on days 1 to 3, repeated every 28 days for eight courses)
Number of subjects: 317
Study 8201375 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant chemotherapy)
Number of subjects: 317
Study 8201375 — intervention group
Group type: EXPERIMENTAL
Intervention: CYVADIC chemotherapy
Number of subjects: 317
Study 8201375 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 317
Study 3662061 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam 0.2 mg/kg
Number of subjects: 60
Study 3662061 — intervention group
Group type: COMPARATOR
Intervention: thiopental 3.5 mg/kg
Number of subjects: 60
Study 31972745 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking group (screw heads blocking superior-adjacent bilateral facets)
Number of subjects: 12
Study 31972745 — intervention group
Group type: COMPARATOR
Intervention: Control group (intact noninstrumented spine)
Number of subjects: 12
Study 31972745 — intervention group
Group type: COMPARATOR
Intervention: Comparison between blocking and control groups
Number of subjects: 12
Study 29549523 — intervention group
Group type: EXPERIMENTAL
Intervention: High cadence (90 r/min) + taurine (50 mg/kg body mass)
Number of subjects: 9
Study 29549523 — intervention group
Group type: COMPARATOR
Intervention: High cadence (90 r/min) + placebo (3 mg/kg body mass maltodextrin)
Number of subjects: 9
Study 29549523 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cadence (50 r/min) + taurine
Number of subjects: 9
Study 29549523 — intervention group
Group type: COMPARATOR
Intervention: Low cadence (50 r/min) + placebo
Number of subjects: 9
Study 28207287 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine
Number of subjects: 70
Study 28207287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 25867422 — intervention group
Group type: EXPERIMENTAL
Intervention: External rhGM‐CSF gel
Number of subjects: 0
Study 25867422 — intervention group
Group type: COMPARATOR
Intervention: rhGM‐CSF gel matrix components (Control)
Number of subjects: 0
Study 24268210 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular Magnetic Resonance (CMR)
Number of subjects: 321
Study 24268210 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography Angiography (CTA)
Number of subjects: 321
Study 24268210 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical management
Number of subjects: 321
Study 24268210 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR or CTA
Number of subjects: 321
Study 21036772 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily regimen of emtricitabine, didanosine and efavirenz
Number of subjects: 355
Study 21036772 — intervention group
Group type: COMPARATOR
Intervention: Protease inhibitor‐based regimen
Number of subjects: 355
Study 18855829 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + voicemail monitoring and telephone counseling
Number of subjects: 304
Study 18855829 — intervention group
Group type: COMPARATOR
Intervention: Telephone-based general support
Number of subjects: 304
Study 16553634 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive metronidazole plus amoxicillin
Number of subjects: 43
Study 16553634 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive metronidazole
Number of subjects: 43
Study 16553634 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 43
Study 16553634 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planning (SRP)
Number of subjects: 43
Study 15292323 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of GH therapy (0.35 U/kg.wk)
Number of subjects: 24
Study 15292323 — intervention group
Group type: COMPARATOR
Intervention: Cessation of GH therapy
Number of subjects: 24
Study 10863716 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 10
Study 10863716 — intervention group
Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 10
Study 8874913 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 micrograms.kg‐1
Number of subjects: 90
Study 8874913 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 30 micrograms.kg‐1
Number of subjects: 90
Study 8874913 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 45 micrograms.kg‐1
Number of subjects: 90
Study 8874913 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group PLAC)
Number of subjects: 90
Study 8874913 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam groups (combined M-15, M-30, M-45)
Number of subjects: 90
Study 1348442 — intervention group
Group type: EXPERIMENTAL
Intervention: High fear exposure
Number of subjects: 65
Study 1348442 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fear exposure
Number of subjects: 65
Study 1348442 — intervention group
Group type: COMPARATOR
Intervention: Moderate fear exposure (control group)
Number of subjects: 65
Study 3874643 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg kg‐1 over 5 s
Number of subjects: 60
Study 3874643 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg kg‐1 over 20 s
Number of subjects: 60
Study 3874643 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg kg‐1 over 60 s
Number of subjects: 60
Study 3874643 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 60
Study 3874643 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-s group
Number of subjects: 60
Study 3874643 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-s group
Number of subjects: 60
Study 3874643 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-s group
Number of subjects: 60
Study 31657982 — intervention group
Group type: EXPERIMENTAL
Intervention: DDIR signature positive
Number of subjects: 425
Study 31657982 — intervention group
Group type: EXPERIMENTAL
Intervention: sTILs density ≥ 20%
Number of subjects: 425
Study 31657982 — intervention group
Group type: EXPERIMENTAL
Intervention: DDIR positivity and T1c/T2N0 disease
Number of subjects: 425
Study 30565735 — intervention group
Group type: EXPERIMENTAL
Intervention: LET's CONNECT (LC)
Number of subjects: 218
Study 30565735 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 218
Study 27387658 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline LDCT screening
Number of subjects: 26004
Study 24709712 — intervention group
Group type: EXPERIMENTAL
Intervention: 50mg tramadol (TRA)
Number of subjects: 19
Study 24709712 — intervention group
Group type: EXPERIMENTAL
Intervention: 100mg tramadol (TRA)
Number of subjects: 19
Study 24709712 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosages (50mg and 100mg)
Number of subjects: 19
Study 22416821 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle albumin:creatinine ratio tertile (n=50)
Number of subjects: 150
Study 22416821 — intervention group
Group type: EXPERIMENTAL
Intervention: High albumin:creatinine ratio tertile (n=50)
Number of subjects: 150
Study 22416821 — intervention group
Group type: COMPARATOR
Intervention: Lower albumin:creatinine ratio tertile (n=50)
Number of subjects: 150
Study 19487320 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol (GBX) 5, 10, and 15 mg
Number of subjects: 81
Study 19487320 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (ZOL) 10 mg
Number of subjects: 81
Study 18031818 — intervention group
Group type: EXPERIMENTAL
Intervention: 1CU accommodating IOL
Number of subjects: 90
Study 18031818 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal IOL
Number of subjects: 90
Study 18031818 — intervention group
Group type: COMPARATOR
Intervention: Monofocal IOL (control group)
Number of subjects: 90
Study 16680965 — intervention group
Group type: EXPERIMENTAL
Intervention: MEBO treatment
Number of subjects: 598
Study 16680965 — intervention group
Group type: COMPARATOR
Intervention: SD-Ag cream treatment
Number of subjects: 598
Study 12934781 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital sign stamp intervention
Number of subjects: 9439
Study 12934781 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no vital sign stamp)
Number of subjects: 9439
Study 10986219 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ornithine-L-aspartate (LOLA) 5 g intravenously
Number of subjects: 15
Study 10986219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9380238 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis patients with elevated plasma silicon levels (3,849 and 2,350 micrograms/l)
Number of subjects: 2
Study 9380238 — intervention group
Group type: COMPARATOR
Intervention: Dialysis patients (n=30)
Number of subjects: 2
Study 9380238 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Si levels
Number of subjects: 2
Study 8229903 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose drink in the morning
Number of subjects: 0
Study 8229903 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated glucose containing drink to sustain high blood glucose levels for 2 hours
Number of subjects: 0
Study 8229903 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of a glucose drink after overnight fasting
Number of subjects: 0
Study 3511835 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Number of subjects: 56
Study 3511835 — intervention group
Group type: COMPARATOR
Intervention: Routine arteriography
Number of subjects: 56
Study 31195867 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated oral solution of misoprostol
Number of subjects: 2
Study 31195867 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 2
Study 29874654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric citrate hydrate
Number of subjects: 60
Study 29874654 — intervention group
Group type: COMPARATOR
Intervention: Lanthanum carbonate (control)
Number of subjects: 60
Study 26892845 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 27
Study 26892845 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 27
Study 25044988 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-complex carbohydrate diet supplemented with long-chain n-3 PUFA (LFHCC n-3)
Number of subjects: 75
Study 22561583 — intervention group
Group type: EXPERIMENTAL
Intervention: HFR‐Aequilibrium (HFR‐Aeq)
Number of subjects: 50
Study 22561583 — intervention group
Group type: COMPARATOR
Intervention: HFR
Number of subjects: 50
Study 20691040 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (antibiotics, analgesics, and/or expectant management)
Number of subjects: 214
Study 20691040 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective resection of the affected colon segment (preferably laparoscopic)
Number of subjects: 214
Study 20691040 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 214
Study 20691040 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective resection
Number of subjects: 214
Study 18941533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho All‐Flex Diaphragm, lubricant gel (Replens) and condoms
Number of subjects: 5045
Study 18941533 — intervention group
Group type: COMPARATOR
Intervention: Condoms alone
Number of subjects: 5045
Study 18941533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho All‐Flex Diaphragm, lubricant gel (Replens) and condoms with consistent use
Number of subjects: 5045
Study 16168735 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-blind subjects
Number of subjects: 0
Study 16168735 — intervention group
Group type: COMPARATOR
Intervention: Sighted subjects
Number of subjects: 0
Study 16168735 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 12652226 — intervention group
Group type: EXPERIMENTAL
Intervention: Anecortave acetate 15 mg
Number of subjects: 128
Study 12652226 — intervention group
Group type: COMPARATOR
Intervention: Anecortave acetate (other doses)
Number of subjects: 128
Study 12652226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 11805185 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 84
Study 11805185 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 84
Study 10413912 — intervention group
Group type: EXPERIMENTAL
Intervention: Bassini technique
Number of subjects: 119
Study 10413912 — intervention group
Group type: EXPERIMENTAL
Intervention: Shouldice technique
Number of subjects: 119
Study 10413912 — intervention group
Group type: EXPERIMENTAL
Intervention: McVay technique
Number of subjects: 119
Study 9422185 — intervention group
Group type: EXPERIMENTAL
Intervention: Injured site tissue oxygenation
Number of subjects: 0
Study 9422185 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-injured site of fractured extremity
Number of subjects: 0
Study 9422185 — intervention group
Group type: COMPARATOR
Intervention: Non-injured extremity
Number of subjects: 0
Study 9422185 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-day 4 oxygenation at both sites
Number of subjects: 0
Study 2111249 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP-masks with 10 cm water pressure
Number of subjects: 47
Study 2111249 — intervention group
Group type: COMPARATOR
Intervention: PEEP-masks with 0 cm water pressure (placebo)
Number of subjects: 47
Study 2111249 — intervention group
Group type: COMPARATOR
Intervention: Control group (0 cm water pressure)
Number of subjects: 47
Study 7457415 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 120, 180, and 240 mg/day
Number of subjects: 10
Study 7457415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6734694 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol 100 to 200 mg/day
Number of subjects: 16
Study 6734694 — intervention group
Group type: EXPERIMENTAL
Intervention: oxprenolol 120 to 240 mg/day
Number of subjects: 16
Study 30170389 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 28
Study 30170389 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Number of subjects: 28
Study 30170389 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful smoking cessation group (n=21)
Number of subjects: 28
Study 30170389 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects (after smoking cessation)
Number of subjects: 28
Study 26503512 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-Regulated Volume Control (PRVC) ventilation
Number of subjects: 11
Study 26503512 — intervention group
Group type: COMPARATOR
Intervention: Conventional Pressure Control (PC) ventilation
Number of subjects: 11
Study 24426817 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem-ER 12.5 mg (bedtime dosing)
Number of subjects: 22
Study 24426817 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg (middle-of-the-night dosing)
Number of subjects: 22
Study 24426817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 22413805 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornase alpha
Number of subjects: 33
Study 22413805 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 33
Study 22413805 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline
Number of subjects: 33
Study 20003568 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g AXOS per day for 3 weeks
Number of subjects: 20
Study 20003568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18091290 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case-managed intervention with incentives and tracking
Number of subjects: 520
Study 18091290 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 520
Study 16371019 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo purging with rituximab
Number of subjects: 27
Study 16371019 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo purging by CD34+ cell selection
Number of subjects: 27
Study 16371019 — intervention group
Group type: COMPARATOR
Intervention: Unpurged patients
Number of subjects: 27
Study 12741433 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (800 mg loading dose, 200 or 400 mg daily maintenance dose depending on renal function)
Number of subjects: 110
Study 11029368 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 400 microgram twice daily
Number of subjects: 38
Study 8812826 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH tobacco use intervention including the promotion of tobacco-free school policies
Number of subjects: 6527
Study 8812826 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH tobacco use intervention
Number of subjects: 6527
Study 1576648 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate 400 mg B.I.d for eight weeks
Number of subjects: 29
Study 1576648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 4061530 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal biophysical profile
Number of subjects: 652
Study 4061530 — intervention group
Group type: COMPARATOR
Intervention: Nonstress test
Number of subjects: 652
Study 30971593 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin infusion at a dose of 2 μg/kg/h
Number of subjects: 0
Study 30971593 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine infusion at a dose of 0.1 μg/kg/min
Number of subjects: 0
Study 30407292 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel and Aspirin
Number of subjects: 136
Study 30407292 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 136
Study 25600111 — intervention group
Group type: EXPERIMENTAL
Intervention: L-T4 treatment
Number of subjects: 25
Study 25600111 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 25
Study 24613271 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive care
Number of subjects: 252
Study 24613271 — intervention group
Group type: COMPARATOR
Intervention: Interdisciplinary care
Number of subjects: 252
Study 24613271 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 252
Study 22266087 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplugged intervention
Number of subjects: 1753
Study 20636228 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-restricted diet (2-3 g/day) and fluid restriction (1.5 L/day)
Number of subjects: 30
Study 20636228 — intervention group
Group type: COMPARATOR
Intervention: General diet information on heart failure
Number of subjects: 30
Study 18304952 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (2 mg/kg/day, three doses a day)
Number of subjects: 40
Study 18304952 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (0.5 mg/kg/day, three doses a day)
Number of subjects: 40
Study 15677832 — intervention group
Group type: EXPERIMENTAL
Intervention: High-guidance group (HG; two group sessions supervised by a physical therapist and one unsupervised home session per week, n = 17)
Number of subjects: 49
Study 15677832 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-guidance group (MG; one supervised group session and two unsupervised home sessions per week, n = 16)
Number of subjects: 49
Study 15677832 — intervention group
Group type: COMPARATOR
Intervention: Control group (C; no exercise, n = 16)
Number of subjects: 49
Study 12898044 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 40